🇺🇸 AG-013736 in United States
27 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 27
Most-reported reactions
- Dehydration — 5 reports (18.52%)
- Enteritis — 3 reports (11.11%)
- Fatigue — 3 reports (11.11%)
- Pneumonia — 3 reports (11.11%)
- Respiratory Failure — 3 reports (11.11%)
- Abdominal Pain — 2 reports (7.41%)
- Acidosis — 2 reports (7.41%)
- Hypertension — 2 reports (7.41%)
- Liver Function Test Abnormal — 2 reports (7.41%)
- Mucosal Inflammation — 2 reports (7.41%)
Other Oncology approved in United States
Frequently asked questions
Is AG-013736 approved in United States?
AG-013736 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for AG-013736 in United States?
University of Wisconsin, Madison is the originator. The local marketing authorisation holder may differ — check the official source linked above.